Introduction
Reproductive history influences risk of ovarian cancer and it has been hypothesized that these associations are mediated by exposure to endogenous hormones, including androgens (1) . Data from experimental studies link androgen-related signalling to ovarian cancer through increased cellular proliferation and reduced apoptotic rates (2) (3) (4) . The relationship between androgens and epithelial ovarian cancer (EOC) risk has been examined in 7 nested case-control studies with the numbers of cases in these studies ranging from 31 to 1,052 (5-10); these studies predominantly investigated EOC as a composite outcome. Emerging data show heterogeneity in risk factors by histologic subtypes (e.g., serous, endometrioid, mucinous, clear cell) and by the hypothesized "dualistic pathway" of ovarian carcinogenesis (defined by differences in the genetic make-up and the morphological architecture of histologic phenotypes) (11) (12) (13) (14) (15) (16) (17) (18) . The relationship between androgens and EOC risk by disease subtype has been minimally explored. Analyses to date suggest heterogeneity by subtype (9, 10) ; however, individual studies evaluating EOC by subtype were either limited by small case numbers in subtype analyses (9) , or restricted to women pregnant at the time of serum sampling (10) .
We pooled and harmonized available data from 6 nested case-control studies within the Ovarian Cancer Cohort Consortium (OC3), plus the Finnish Maternity Cohort (FMC), to investigate the relationship of pre-diagnosis concentrations of androgens (e.g., testosterone, free testosterone, androstenedione, dehydroepiandrosterone-sulfate (DHEAS)) and sex-hormone binding globulin (SHBG) with EOC risk, overall and by subtype. Subtype analyses included analyses by histology, grade and stage, and by the hypothesized dualistic model of EOC development, i.e., type I vs. type II (19). Our study represents the largest investigation to date including individual-level data from 1,331 EOC cases and 3,017 matched controls, with 61 (clear cell) to 667 (serous) cases represented in the major histologic subtypes.
Methods

Study Population: Ovarian Cancer Cohort Consortium (OC3)
The OC3 has been described previously (12) . For this investigation, eligible cohorts were required to have data on a defined set of a priori selected covariates (e.g., menopausal status at blood donation, oral contraceptive use at blood donation, parity) and pre-diagnosis measurements of testosterone, free testosterone, androstenedione or DHEAS. In addition to the OC3 cohorts, the FMC, a cohort of women pregnant at blood collection, contributed data to this investigation (for contributing cohorts see Supplementary Table S1 ). Available biomarker and questionnaire data from each cohort were centrally collated and harmonized at the Data Coordinating Center at the Brigham and Women's Hospital.
Case characteristics
Eligible cases included women diagnosed with invasive EOC (International Classification of Disease
Codes (ICD): ICD9 codes 183 and 158; ICD10 code C56) ascertained by self-report with medical record confirmation and/or linkage to cancer registries. Cases were individually matched to two or three controls (free of cancer and alive at the time of diagnosis of the index case) on age, date, menopausal status and day or phase of menstrual cycle at blood collection in premenopausal women, with the exception of the FMC (matched on age and date at blood collection, parity at blood collection and at diagnosis/index date). Histomorphological data was complete, and the majority of cases had data on stage (82%); grade was available for 36% of the cases. We used histology and grade to classify tumors into type I ((48%, n=291); low-grade serous and endometrioid, all mucinous and clear cell) and type II ((52%, n=314); high-grade serous, high-grade endometrioid) (19). Serous and endometrioid cases missing grade data were excluded from these analyses; mucinous and clear cell tumors were included regardless of grade data availability, as these tumors are classified as type I independent of grade. In a sensitivity analysis, all mucinous and clear cell cases missing grade were excluded from the type I subgroup (after exclusion, case n=77). The proportion of type I tumors was higher than expected; however, we observed the expected distribution (type I: 28% vs. type II: 72%) after excluding women from the FMC (all missing grade; younger at diagnosis and more frequently diagnosed with mucinous tumors than cases from the other cohorts).
Laboratory methods
In all studies, case-control sets were measured in the same batch and technicians performing the assays were blinded to case-control status and quality control samples. Information on sample type, laboratory assays, and intra-and inter-batch coefficients of variations for each cohort is summarized in Supplemental Table S2 . Free testosterone was calculated based on measured concentrations of testosterone and SHBG, with albumin assumed to be a constant 40g/L, according to the mass law of action (20).
Statistical analyses
Hormone measurements were standardized across studies based on the cohort-specific mean concentrations in controls (see supplemental methods; Supplemental Table S3 ). Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). ORs were estimated using log2-transformed biomarker concentrations and study-specific tertiles based on the distribution in controls. A continuous probit score, generating a rank for each participant in each cohort by hormone concentration, was used to test for trend across tertiles. We additionally evaluated associations in quintiles for EOC overall and the serous subtype. Multivariable models included: parity [never, ever, missing (2.8%)] and OC use [never, ever, missing (47%); excluding FMC 2.3% missing].
Additional adjustment for body mass index (BMI; kg/m 2 ) among women with data available (n=747 cases), did not change the ORs (data not shown).
Statistical analyses were conducted using a two-stage approach: First, ORs were calculated within each cohort and pooled using DerSimonian and Laird random effects meta-analysis models to assess between-study heterogeneity (21). Second, ORs were calculated based on pooled individual participant data (22). ORs estimated from meta-analysis and the data pooling method were similar, and we observed no significant between-study heterogeneity. Therefore, presented results are based on the pooled analysis. The assumption of linearity was tested using restricted cubic splines; no significant deviations from linearity were observed. Statistical heterogeneity of associations across subtypes was assessed via a likelihood ratio test comparing a model allowing the association for the risk factor of interest to vary by subtype versus one assuming the same association across subtype using polytomous conditional logistic regression (23).
We evaluated associations after stratification by menopausal status at blood collection (premenopausal vs. postmenopausal) and age at diagnosis (<55 vs. ≥55 years). Androgen concentrations are relatively stable in pregnancy (24), however, we excluded FMC members in sensitivity analyses given that all women were pregnant at the time they provided a blood sample. Finally, we conducted a sensitivity analysis after exclusion of women diagnosed within two years after blood donation. A more detailed description of statistical procedures is available in the supplemental methods.
SAS Statistical Software, version 9.3 (SAS Institute, Cary NC, USA) was used for statistical analyses.
P-values<0.05 were considered as statistically significant; all statistical tests and p-values were twosided.
Results
In total 1,331 cases and 3,017 matched controls from 7 cohorts were included in this investigation (Table 1) . Average age at blood collection ranged from 32 (FMC) to 61 years (CLUE II), and the majority of women were parous (89% cases, 94% controls) ( Table 1) . Average age at diagnosis ranged from 45 (FMC) to 67 (CLUE II) (Supplemental Table S4 ). Table 2 ). Free testosterone, androstenedione, DHEAS and SHBG were not associated with overall risk of EOC.
Androgens and overall EOC risk
Results from analyses evaluating quintiles of androgen and SHBG concentrations were similar to those from models using tertiles (Supplemental Table S5 case-control sets). However, while of the same general magnitude, the effect estimates were no longer statistically significant (Supplemental Figure S1 ).
Sensitivity and Subgroup Analyses
We observed some evidence of heterogeneity for the androgens and SHBG and overall EOC by 
Discussion
We investigated pre-diagnosis circulating concentrations of androgens and risk of EOC overall (n=1,331 cases) and by subtype (case range, n=61 clear cell to 667 serous), in a collaborative re-analysis of 7 nested case-control studies. The association between testosterone and risk of EOC differed by histologic subtype: endogenous androgens were predominantly associated with increased risk of endometrioid and mucinous tumors, while no significant associations were observed for serous or clear cell tumors, although some androgens were inversely associated with high-grade serous and endometrioid (Type II) disease.
Ovarian cancer is comprised of four predominant histologic subtypes: serous, mucinous, endometrioid and clear cell. These histologic subtypes differ substantially by molecular alterations at diagnosis and Prior epidemiologic data suggest risk factor differences by EOC subtype defined by histology (e.g. (12, (15) (16) (17) (18) ) and developmental pathway (11, 14) . Consistent differences by histologic subtype of invasive EOC are observed for hormone-related risk factors including duration of OC use (lower risk of all histologic subtypes but mucinous; (12, 15)), older age at menopause (higher risk of all but mucinous; (12)), smoking (higher risk of mucinous, lower risk of clear cell; (12, 17) ), parity (more strongly protective in non-serous subtypes; (12)), postmenopausal hormone therapy (HT) use (higher risk of serous and endometrioid subtypes only; (12, 18)), and adiposity (among non-HT users; higher risk of serous and endometrioid subtypes only); (16)). Data by the type I/II classification are sparse, but consistently show stronger associations between parity and type I, relative to type II, disease (11, 14) .
Three prospective studies evaluated circulating estrogens (10, 28) and/or androgens (9, 10) and invasive EOC risk by subtype. Higher concentrations of both estrogens and androgens were associated with increased risk of non-serous EOC subtypes (9, 10, 28), whereas higher concentrations of androstenedione had opposing effects on risk of type I (higher risk) and type II (lower risk) EOC (9).
In women, androgens are produced in the ovary, adrenal glands, and via peripheral conversion of androgen precursors (e.g., DHEA); in turn, androgens are the substrate for estrogen production by In vivo data show that ovarian cancer preferentially develops in a hormonal milieu enriched with androgens (e.g., testosterone induces epithelial neoplasms in guinea pigs (37)) or estrogens (e.g., estrogen-induced tumor growth in highgrade serous ovarian cancers) (38, 39) . The hyperandrogenic PCOS is characterized by functional ovarian hyperandrogenism, with an excess of testosterone produced in the ovarian thecal cells (40) ; up to 45% of cases additionally present with adrenal hyperandrogenism (41) . Estimates of PCOS prevalence range from 5 to 15% (30); the syndrome has highest prevalence among reproductive-age women. PCOS-related androgen excess is observed in both pre-and postmenopausal women (42) .
Progesterone deficiency is a hallmark of PCOS, resulting in a higher ratio of estrogens to progesterone.
PCOS (43, 44) and relatively high levels of estrogens unopposed by progesterone are associated with increased endometrial cancer risk (i.e., estrogen-alone HT (45) , relatively high endogenous estrogens in postmenopausal women (33, 46)). These associations with endometrial cancer may be most relevant to the endometrioid or clear cell EOC, given endometrial tissue is a proposed tissue of origin for these subtypes. PCOS itself has not consistently been associated with ovarian cancer (43, 44, 47) , though data by subtype are limited. Data to date suggest both estrogen-alone and estrogen plus progesterone HT are associated with increased risk of endometrioid EOC (18).
In the current study, we evaluated three members of the androgen synthesis pathway-DHEAS, androstenedione, testosterone-and EOC risk by histology (i.e., accounting for hypothesized differences in cell of origin) and developmental pathway (i.e., "less" relative to "more" aggressive disease). We We adjusted for BMI in a sensitivity analysis, given (1) the association between PCOS and obesity and Given the large sample size, our study was powered to investigate risk associations for less common tumors (e.g., mucinous tumors) and by developmental pathway (type I/type II). A general weakness of pooled analyses is the difference in data availability of covariates and differences in laboratory methods.
In this investigation, data from each cohort were centrally compiled and harmonized and we addressed differences in absolute biomarker concentrations (I) using study-specific tertiles and (II) standardizing hormone measurements using study-specific mean concentrations. Results were robust regardless of whether we calculated ORs from the pooling of individual data or from meta-analysis. For some of the investigated hormones the number of sets that could be used was reduced for subgroup analyses, which resulted in reduced power. In our primary analyses using the developmental pathway classification, we The testosterone synthesis pathway (e.g., DHEAS, androstenedione, testosterone) may play an important role in the onset and progression of a subset of epithelial invasive ovarian carcinomas.
Androgens may either have a direct impact on ovarian carcinogenesis, or act through increased synthesis of other steroid hormones (e.g., estrogens); this is an area for future epidemiologic research.
While androgens were associated with increased risk of non-serous tumors, we observed an inverse association between androstenedione and high grade serous tumors. In addition to providing novel findings on hormone-related pathways in ovarian carcinogenesis, this study supports emerging data on the heterogeneity of epithelial invasive ovarian cancer and underscores the importance of examining etiologic differences for subtypes. 1 Results were derived from conditional logistic regression models, additionally adjusted for OC use (never/ever/missing) and parity (never/ever/missing); 2 The p value for trend across tertiles is based on a continuous probit score (generating a rank for each person in each cohort by hormone level); 3 Linear trends for doubling of hormone concentrations were estimated on log2 scale; 4 Pair-wise heterogeneity tests were performed, using the likelihood ratio test comparing models assuming (1) the same association between exposure and outcomes compared to (2) a model assuming different associations for each subtype. DHEAS=dehydroepiandrosterone sulfate; SHBG=sex hormone binding globulin 
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1 Results were derived from conditional logistic regression models, additionally adjusted for OC use (never/ever/missing) and parity (never/ever/missing). Pair-wise heterogeneity tests were performed, using the likelihood ratio test comparing models assuming (1) the same association between exposure and outcomes compared to (2) a model assuming different associations for each subtype. 2 Comparing all high grade subtypes to low grade. 3 Comparing high grade serous to all low grade. DHEAS=dehydroepiandrosterone sulfate; SHBG=sex hormone binding globulin Title: Odds ratios (95% CI) for EOC for doubling of androgen concentrations and EOC risk by the Type I and Type II classification: the Ovarian Cancer Cohort Consortium (OC3).
Results were derived from conditional logistic regression models, additionally adjusted for OC use (never/ever/missing) and parity (never/ever/missing). Pair-wise heterogeneity tests were performed, using the likelihood ratio test comparing models assuming (1) the same association between exposure and outcomes compared to (2) 
Selection of case patients and control participants
EOC cases in the participating cohorts are ascertained by (1) self-report with subsequent medical record confirmation (2) and/or linkage to cancer registries that in each study generally is estimated to be >95% complete. Analyses were limited to women diagnosed with invasive ovarian carcinomas and with data on histologic subtype.
Data on tumor characteristics
The OC3 database contained complete information on histomorphology: 50% of tumors were of serous histology (n=667), 15% mucinous (n=193), 12% endometrioid (n=166), 5% clear To account for potential interference of exogenous hormones with circulating concentrations [2] , women using OC or HT at the time of blood collection were either: (1) excluded a priori (e.g., EPIC, NHS II premenopausal) or (2) cases and controls were matched on HT use at blood donation (e.g., CLUE II, NHS, NHS II postmenopausal or WHS). It was presumed that FMC participants (pregnant at blood collection) were not using exogenous hormones at the time of blood donation.
Laboratory methods
All participating studies used a nested case-control design, with assays arranged so that casecontrol sets were measured in the same batch and technicians performing the assays were blinded to case-control status and quality control samples. Hormone concentrations were measured in serum in EPIC (except Sweden), FMC and the NYUWHS; heparin plasma specimens were used in CLUEII and the NHS and NHS II; and EDTA plasma was used for
Harvard WHS and Swedish participants from the EPIC cohort. The assays used, along with intra-and interbatch coefficients, are presented in Table S2 . Free testosterone was calculated for CLUE II, EPIC, FMC and NYUWHS, based on measured concentrations of testosterone and SHBG, with albumin assumed to be a constant 40g/L, according to the mass law of action [3] .
Statistical analyses
Outliers were identified and removed using the ESD approach [4] . As biomarker data deviated from the normal distribution, we applied the log2 transformation to limit heteroscedasticity. To account for differences in study-specific mean concentrations and a slightly different case-control ratio between studies (1:2 vs. 1:3), data were standardized based on the cohort-specific mean concentrations in controls (Table S3) .
Statistical analyses were conducted using a two-stage approach (I) using random effect metaanalyses and (II) an aggregated data approach based on individual participant data. First, the log2 relative risks were calculated from conditional logistic regression models within each cohort and pooled using DerSimonian and Laird random effects models (random effects pooling, [5] ). Heterogeneity between cohort-specific effect estimates was tested by
DerSimonian and Lairds Q statistic [5] and conducted for all analyses (invasive EOC, by histologic subtype, stage, grade, type I / type II model, menopausal status at blood donation, age at diagnosis and exclusion of women diagnosed within 2 years after blood donation).
NHS, NHS II and WHS data were combined for meta-analysis, as these studies were evaluated together in a previous publication [6] , and specimens were analyzed in the same laboratory. Based on the relatively small case numbers in some cohorts (e.g., CLUE II: cases n=46) meta-analyses were performed in the crude model (accounting for matching factors), and limited to cohorts contributing more than 5 cases for any given subgroup analyses.
Second, in the aggregated approach, individual participant data from all cohorts were pooled and a combined effect estimate was calculated from a conditional logistic regression model [7] . The original matched sets were retained for all statistical analyses. 3 Patients were asked to provide follicular sample at 3-5 days and luteal sample at 7-9 days before anticipated start of the next cycle. 4 RCT = Randomized Controlled Trial. Table S5 . Odds ratios (95% CI) for invasive EOC overall and the serous subtype in quintiles of androgen and SHBG concentrations: OC3 Figure S1 . Odds ratios (95% CI) for doubling of androgen concentrations and Type I EOC restricted to cases with data on tumor grade (p het comparing type I and type II: testosterone, 0.09; free testosterone, 0.38; androstenedione, <0.01; DHEAS, 0.03; SHBG, 0.14; type II ORs shown in Figure  1 ): the Ovarian Cancer Cohort Consortium (OC3)
Results were derived from conditional logistic regression models, additionally adjusted for OC use (never/ever/missing) and parity (never/ever/missing). Pair-wise heterogeneity tests were performed, using the likelihood ratio test comparing models assuming (1) the same association between exposure and outcomes compared to (2) a model assuming different associations for each subtype. DHEAS=dehydroepiandrosterone sulfate; SHBG=sex hormone binding globulin
